These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 8075592)

  • 1. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.
    Vadhan-Raj S
    Stem Cells; 1994 May; 12(3):253-61. PubMed ID: 8075592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
    Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
    Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A GM-CSF/IL-3 fusion protein promotes neutrophil and platelet recovery in sublethally irradiated rhesus monkeys.
    Williams DE; Dunn JT; Park LS; Frieden EA; Seiler FR; Farese AM; Macvittie TJ
    Biotechnol Ther; 1993; 4(1-2):17-29. PubMed ID: 8374510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321.
    Anderson JE; Appelbaum FR
    Curr Opin Hematol; 1994 May; 1(3):203-9. PubMed ID: 9371283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid cytokines as hematopoietic growth factors.
    Williams DE; Park LS; Broxmeyer HE; Lu L
    Int J Cell Cloning; 1991 Nov; 9(6):542-7. PubMed ID: 1770228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on human polymorphonuclear leukocyte function.
    Buescher ES; McIlheran SM; Banks SM; Vadhan-Raj S
    Exp Hematol; 1993 Oct; 21(11):1467-72. PubMed ID: 8405227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
    Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-3 in hematology and oncology: current state of knowledge and future directions.
    Mangi MH; Newland AC
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):87-95. PubMed ID: 10515681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocyte-macrophage colony stimulating factor and interleukin 3: target cells and kinetics of response in vivo.
    Aglietta M; Pasquino P; Sanavio F; Stacchini A; Severino A; Fubini L; Morelli S; Volta C; Monteverde A; Piacibello W
    Stem Cells; 1993 Jul; 11 Suppl 2():83-7. PubMed ID: 8401260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration.
    Farese AM; Casey DB; Smith WG; Vigneulle RM; McKearn JP; MacVittie TJ
    Stem Cells; 2001; 19(6):522-33. PubMed ID: 11713344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-3 (IL-3) receptors on rhesus monkey bone marrow cells: species specificity of human IL-3, binding characteristics, and lack of competition with GM-CSF.
    van Gils FC; Budel LM; Burger H; van Leen RW; Löwenberg B; Wagemaker G
    Exp Hematol; 1994 Mar; 22(3):248-55. PubMed ID: 7509288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro production of megakaryocytes from PIXY321 versus GM-CSF-mobilized peripheral blood progenitor cells.
    Lefebvre P; Winter JN; Rademaker AW; Goolsby C; Cohen I
    Stem Cells; 1997; 15(2):112-8. PubMed ID: 9090787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of hematopoietic myeloid and megakaryocyte toxicity associated with zidovudine in vivo in mice with recombinant GM-CSF.
    Gallicchio VS; Hughes NK; Tse KF
    Growth Regul; 1994 Jun; 4(2):41-7. PubMed ID: 7950902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin 3 fusion protein, on human tumor colony-forming units taken directly from patients.
    Izquierdo MA; Degen D; Raymond E; Caron D; Ortiz V; Banks P; Von Hoff DD
    Clin Cancer Res; 1996 Oct; 2(10):1713-6. PubMed ID: 9816121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin and chemokine mRNA expression in patient post-chemotherapy and in vitro cytokine-treated marrow stromal cell layers.
    Schwartz GN; Kammula U; Warren MK; Park MK; Yan XY; Marincola FM; Gress RE
    Stem Cells; 2000; 18(5):331-42. PubMed ID: 11007917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study.
    Vadhan-Raj S; Broxmeyer HE; Andreeff M; Bandres JC; Buescher ES; Benjamin RS; Papadopoulos NE; Burgess A; Patel S; Plager C; Hittelman WN; McAlister I; Garrison L; Williams DE
    Blood; 1995 Sep; 86(6):2098-105. PubMed ID: 7662957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
    Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
    J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.